Bavarian Nordic enters license agreement with Nuance Pharma on RSV candidate
Nuance Pharma, a Shanghai-based biotech company, gains the commercial rights in a string of Asian countries for Bavarian Nordic’s RSV vaccine candidate.
by CHRISTIAN BUNDGAARD, translated by daniel pedersen
On Monday, Bavarian Nordic announced that a license and supply agreement has been completed with Shanghai-based biotech company Nuance Pharma, regarding the rights for the Danish company’s RSV vaccine candidate, a stock notification reports.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Bavarian Nordic expects revenue setback in 2022
For subscribers
.jpg&w=384&q=75)
